Vantage logo

Disaster strikes for Akebia

Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?

Vantage logo

Axsome rides the bull case

Axsome is heading to regulators in the wake of a second successful depression study, and investors are predicting huge success. What could possibly go wrong?